

CERTIFICATE UNDER 37 C.F.R. § 3.73(b)Applicants: Marc Feldmann and Ravinder N. MainiApplication N : 09/754,004 Filed: January 3, 2001For: TNF α ANTAGONISTS AND METHOTREXATE IN THE TREATMENT OF TNF-MEDIATED DISEASEThe Kennedy Institute of Rheumatology, a Corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

certifies that it is

- A. ☒ the assignee of the entire right, title and interest in the patent application identified above.
- B. ☐ an assignee together with [] of the entire right, title and interest in the patent application identified above. A separate Certificate under 37 CFR § 3.73(b) is attached.

The right, title and interest of the above-named assignee in the patent application identified above is established by virtue of:

- A. ☒ An assignment from the inventors of the patent application identified above. The assignment was recorded in the Patent and Trademark Office at Reel 8168, Frame 0822-0824, or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s) of the patent application identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are attached.☐ Copies of assignments or other documents in the chain of title are attached.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: 18/4/2001Name: Ravinder N. MainiTitle: Director, The Kennedy Institute of RheumatologySignature: R. Maini

::ODMA\RHODMA\Manage\215364:1

Applicant Marc Feldmann, et al.
Client Kennedy Institute (1481) File No. 65019-DA-PCT-US Atty. JPW/AJM/NFM
Date June 17, 2003

Kindly acknowledge receipt of the accompanying

AMENDMENT IN RESPONSE TO JANUARY 17, 2003 OFFICE ACTION AND PETITION FOR A TWO-MONTH EXTENSION OF TIME in connection with Marc Feldmann, et al., TNF α ANTAGONISTS AND METHOTREXATE IN THE TREATMENT OF TNF-MEDIATED DISEASE, U.S. Serial No. 09/754,004, filed January 3, 2001, including Exhibits A-C, a check in the amount of \$410.00 and a Certificate of Mailing dated June 17, 2003.

Due date: June 17, 2003

by placing your receiving date stamp hereon and returning to us.

FILE

Applicants: Marc Feldmann and Ravinder N. Maini

Serial No.: 09/754,004

Examiner: P. Gambel

Filed : January 3, 2001

Group Art Unit: 1644

For : TNF α ANTAGONISTS AND METHOTREXATE IN THE TREATMENT OF TNF-MEDIATED DISEASECommissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**OFFICIAL**

June 17, 2003

S I R:

Transmitted herewith is an amendment to the above identified application.

Small entity status of this application under 37 C.F.R. §1.9 and §1.27 has been established by a verified statement previously submitted.

A verified statement to establish small entity status under 37 C.F.R. §1.9 and §1.27 is enclosed.

X No additional fee is required.

The filing fee is calculated as follows:

	NUMBER AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		NUMBER OF EXTRA CLAIMS PRESENTED		RATE			FEE	
							SMALL ENTITY	OTHER ENTITY		SMALL ENTITY	OTHER ENTITY
Total Claims	15	-	38	=	0	X	\$9	\$18	=	0	0
Independent Claims	1	-	4	=	0	X	\$42.00	\$84.00	=	0	0
Multiple Dependent Claim(s) Presented Yes <u>X</u> No							\$140	\$280	0	0	0
For First Time							TOTAL ADDITIONAL FEE \$ 0				

*If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 20, write "20" in this space.

**If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 3, write "3" in this space.

***If the difference between the "NUMBER AFTER AMENDMENT" and the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than "0", write "0" in the space.

Applicants: Marc Feldmann and Ravinder N. Maini
Serial No.: 09/754,004
Filed : January 3, 2001

Amendment Transmittal Letter
Page Two

The "HIGHEST NUMBER PREVIOUSLY PAID FOR" (Total or Independent) is the highest of the "NUMBER AFTER AMENDMENT" in any prior amendment of the number of claims as originally filed

— Please charge Deposit Account No. 03-3125 in the amount of \$. Three copies of this sheet is enclosed.

X A check in the amount of \$ 410.00 is enclosed, for a two-month extension of time.

X The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposition Account No. 03-3125. Three copies of this sheet are enclosed.

X Any filing fees under 37 C.F.R. §1.16 for the presentation of extra claims.

X Any patent application processing fees under 37 C.F.R. §1.17.

Respectfully submitted,

John P. White
Registration No. 28,678
Alan J. Morrison
Registration No. 37,399
Attorneys for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents, P.O. Box
1450, Alexandria, VA 22313-1450

Alan J. Morrison
Reg. No. 37,399

Date
6/17/03

COOPER & DUNHAM LLP

ATTORNEYS AT LAW

1185 AVENUE OF THE AMERICAS, NEW YORK, NEW YORK 10036

TELEPHONE: (212) 278-0400

FACSIMILE: (212) 391-0525
(212) 391-0526
(212) 391-0630

CHRISTOPHER C. DUNHAM
NORMAN H. ZIVIN
JOHN P. WHITE
WILLIAM E. PELTON
ROBERT D. KATZ
DONNA A. TOBIN
RICHARD S. MILNER
RICHARD F. JAWORSKI
PAUL TENG
PEDRO C. FERNANDEZ
MICHAEL F. MORANO
JASON S. MARIN
KEITH J. BARRAUS
HARVEY AGOSTO
ANTHONY V. FLINT
ARIAN A. BARYALAI
ASHTON J. DELAUNEY
CINDY YANG
RON BILLINGSLEY

IVAN S. KAVRUKOV
PETER D. MURRAY
JAY H. MAIOLI
ROBERT B. G. HOROWITZ
PETER J. PHILLIPS
WENDY E. MILLER
ROBERT T. MALDONADO
ERIC D. KIRSCH
ALAN J. MORRISON
GARY J. GERSHIK
CHRISTINE S. NICKLES
SPYROS S. LOUKAKOS
MARIA V. MARUCCI
DEEPRO R. MUKERJEE
PAUL S. LIM
AUDE GERSPACHER
JEFFREY C. SHIEN
NARESH SRITHARAN

OFFICIAL

Phillip Gambel
8/25/03

FACSIMILE TRANSMISSION

OF COUNSEL
DONALD S. DOWDEN
JOHN R. GARBER
MARK A. FARLEY

SCIENTIFIC ADVISORS
BRIAN J. AMOS, PH.D.
NICHOLAS F. MUTO, PH.D.
JOSEPH D. CRYSTAL, PH.D.
ARMAND L. BALBONI, M. PHIL.
MURIEL M. LIBERTO, PH.D.
ANNE C. MARINOVIC, PH.D.
ANTHONY C. KHONG, PH.D.
JOHN X. MADERMAN, PH.D.

FOUNDED 1867
www.cooperdunham.com

*NEW YORK STATE BAR ADMISSION PENDING

PLEASE DELIVER THE FOLLOWING PAGES

TO : Examiner Phillip Gambel
COMPANY/FIRM : U.S. Patent and Trademark Office
FACSIMILE NO.: (703) 746-5293
FROM : Alan J. Morrison/NFM
TOTAL NUMBER OF PAGES, INCLUDING COVER PAGE: 33
DATE : August 25, 2003 TIME:

IF YOU DO NOT RECEIVE ALL THE PAGES, PLEASE CALL BACK AS SOON AS POSSIBLE TO (212) 278-0400.

MESSAGE: Re: U.S. Serial No. 09/754,004

Further to your August 24, 2003 voice mail request to Dr. Nicholas Muto of our office, we transmit herewith by facsimile copies of (1) an April 23, 2001 Revocation of Powers of Attorney and Appointment of New Attorneys and/or Agents, and (2) a June 17, 2003 Amendment in Response to January 17, 2003 Office Action and Petition for a two-month Extension of Time filed in connection with the above-identified application. Please note that an Information Disclosure Statement was filed on June 20, 2003 in connection with this application. If you are also not in receipt of this IDS, please let us know. Thank you.

=====

THE INFORMATION CONTAINED IN THIS FACSIMILE TRANSMISSION IS INTENDED SOLELY FOR THE PERSONAL AND CONFIDENTIAL USE OF THE DESIGNATED RECIPIENT(S) NAMED ABOVE. THIS TRANSMISSION MAY BE AN ATTORNEY-CLIENT COMMUNICATION CONTAINING INFORMATION THAT IS PRIVILEGED AND CONFIDENTIAL. IF THE READER OF THIS MESSAGE IS NOT A DESIGNATED RECIPIENT OR AN AGENT RESPONSIBLE FOR DELIVERING IT TO A DESIGNATED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECEIVED THIS DOCUMENT IN ERROR, AND THAT ANY REVIEW, DISTRIBUTION, OR COPYING OF THIS MESSAGE IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, OR IF UPON READING THIS DOCUMENT YOU HAVE REASON TO BELIEVE THAT THE DOCUMENT WAS INADVERTENTLY SENT TO YOU, PLEASE NOTIFY US IMMEDIATELY BY COLLECT TELEPHONE CALL AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL. THANK YOU.